Fludiazepam,[2] marketed under the brand name Erispan (エリスパン)[3][4] is a potent benzodiazepine and 2ʹ-fluoro derivative of diazepam,[5] originally developed by Hoffmann-La Roche in the 1960s.[6] It is marketed in Japan and Taiwan.[citation needed] It exerts its pharmacological properties via enhancement of GABAergic inhibition.[7] Fludiazepam has 4 times more binding affinity for benzodiazepine receptors than diazepam.[8] It possesses anxiolytic,[9][10][11] anticonvulsant, sedative, hypnotic and skeletal muscle relaxant properties.[12] Fludiazepam has been used recreationally.[13]
Clinical data | |
---|---|
Trade names | Erispan (JP, TW) |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral (tablets) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.292.343 |
Chemical and physical data | |
Formula | C16H12ClFN2O |
Molar mass | 302.7 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |